Navigation Links
Cambrex Reports Second Quarter 2014 Financial Results
Date:8/1/2014

and Chief Executive Officer in this document.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2013, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, changes in foreign exchange rates, uncollectible receivables, the timing of orders, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products and continued demand in the U.S. for late stage clinical products or the successful outcome of the Company's investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on t
'/>"/>

SOURCE Cambrex Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Cambrex Manufacturing Facility Completes Successful US FDA Inspection
2. Cambrex to Present at Oppenheimer 24th Annual Healthcare Conference
3. Cambrex To Present At UBS Global Healthcare Conference
4. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
5. Cambrex Reports Second Quarter 2012 Results
6. Cambrex to Announce Fourth Quarter 2011 Financial Results on February 6, 2012
7. Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com
8. United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
9. Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com
10. Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz
11. Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel drug ... Eye Institute (NEI) at the National Institutes of Health ... to develop a drug-eluting intraocular lens (IOL) for cataract ... vision loss in people over age 40 and the ... Mandell, LayerBio’s Founder and CEO, "There is a critical ...
(Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... risks of synthetic biology for the nation,s defense and ... and synthetic biology community in an open-source format. ... helps detect the use of synthetic DNA as bioterrorism ... led by Jean Peccoud, associate professor at Virginia Bioinformatics ...
... working to develop a new drug that will regenerate ... after a person is exposed to deadly chemical warfare ... The Ohio State University (OSU), is leveraging Ohio Supercomputer ... antidote to lethal chemicals called organophosphorus (OP) nerve agents. ...
... M. Gorun is leading a research team to ... The work is based on organic catalytic framework ... bonds with a combination of aromatic and aliphatic ... research recently received first place recognition at the ...
Cached Biology Technology:Open-source software designed to minimize synthetic biology risks 2OSU chemist developing solution to nerve agent exposure 2NJIT professor develops a biologically inspired catalyst, an active yet inert material 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... the Ecological Society of America's 91st Annual Meeting, many ... results of their research from the region. Below, ... declines in Hemlocks and the future of the Great ... PM, Exhibit Hall, Cook Convention Center , The Hemlock ...
... release , A motion-triggered camera trap set up in a ... the wild on the island of Borneo, World Wildlife Fund and ... to be one of a population of as few as 13 ... the interior forests of Sabah, Malaysia, an area known as the ...
... therapeutic dose of radiation lost up to 39% of ... inner bone's weight bearing connections by up to 64%, ... edition of the Journal of Applied Physiology, has implications ... long space flights. , "We were really surprised at ...
Cached Biology News:Ecosystem services and invasive species 2Ecosystem services and invasive species 3WWF captures first-ever photo of wild rhino on Borneo 2One therapeutic dose of radiation causes 30 percent spongy bone loss in mice 2One therapeutic dose of radiation causes 30 percent spongy bone loss in mice 3
Request Info...
... automated perfusion system. For real-time or ... biophysics, electrochemistry, or general liquid-handling research ... millisecond accuracy Run experiments automatically ... accuracy and flexibility Turnkey perfusion ...
Recombinant Human PTP1B (aa 2-321), CF...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: